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Abstract
Background and Aims: Flawed ABC transporter functions may contribute to increased risk of drug-induced liver injury
(DILI). We aimed to analyse the influence of genetic variations in ABC transporters on the risk of DILI development and
clinical presentations in a large Spanish DILI cohort.
Methods: A total of ten polymorphisms in ABCB1 (1236T.C, 2677G.T,A, 3435T.C), ABCB4 (1954A.G) and ABCC2
(21774G.del, 21549A.G, 224C.T, 1249G.A, 3972C.T and 4544G.A) were genotyped using Taqman 59 allelic
discrimination assays or sequencing in 141 Spanish DILI patients and 161 controls. The influence of specific genotypes,
alleles and haplotypes on the risk of DILI development and clinical presentations was analysed.
Results: None of the individual polymorphisms or haplotypes was found to be associated with DILI development. Carriers
homozygous for the ABCC2 21774del allele were however only found in DILI patients. Hence, this genotype could
potentially be associated with increased risk, though its low frequency in our Spanish cohort prevented a final conclusion.
Furthermore, carriers homozygous for the ABCC2 21774G/21549A/224T/1249G/3972T/4544G haplotype were found to
have a higher propensity for total bilirubin elevations when developing DILI.
Conclusions: Our findings do not support a role for the analysed polymorphisms in the ABCB1, ABCB4 and ABCC2
transporter genes in DILI development in Spanish patients. The ABCC2 21774deldel genotype was however restricted to
DILI cases and could potentially contribute to enhanced DILI susceptibility.
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Introduction
Drug-induced liver injury (DILI) is an adverse drug reaction of
special concern due to its potentially severe consequences. Despite
increased research in this area over the last decades, the
underlying mechanisms of DILI are not fully understood.
However, host genetic variations are believed to be essential
components in DILI development. Many DILI studies to date
have focused on variations in genes involved in phase I
(bioactivation) and II (detoxification) of drug metabolism and
several potential risk alleles have been identified [1]. Increasing
attention is being paid to the role of phase III (elimination)
proteins in DILI. This group consists mainly of ATP-binding
cassette (ABC) transporters, which are involved in the cellular
efflux of various endogenous and exogenous compounds, includ-
ing therapeutic drugs. The number of transporters in the cell
membrane and their functional level can therefore potentially
influence drug pharmacokintetics/pharmacodynamics and lead to
interindividual differences in drug elimination.
Among the transporters the most investigated for its relationship
with DILI is the bile salt export pump protein (BSEP), which
mediates the efflux o bile acids from hepatocytes into the bile
canaliculus. Interference with BSEP function using in vitro models
has been shown to be highly predictive of liver injury in drug
development [2]. Besides, a genetic variation in ABCB11, which
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encodes BSEP, has been linked to the risk of hepatocellular DILI
in a large population of DILI patients from a Spanish Registry [3].
Less is known regarding the role of other transporters in
hepatotoxicity. P-glycoprotein (P-gp) is the major drug transporter
recognizing a wide range of substrates. In the liver P-gp is located
in the canalicular membrane, where it facilitates biliary drug
excretion. This transporter is encoded by the ABCB1 gene, which
contains 29 exons in a genomic region spanning 209.6 kb [4]. P-
glycoprotein is a well-known determinant in multidrug resistance,
in particularly in chemotherapy. Overexpression in tumour cells
can lead to enhanced drug excretion, which subsequently inhibits
the drug to reach a pharmacologically active concentration [5]. In
addition, ABCB1 has been suggested to play a role in specific forms
of hepatotoxicity [6–8].
The multidrug resistance protein 2 (MRP2), encoded by the
ABCC2 gene, is likewise involved in drug transport. It is confined
to the apical membrane of various polarized cells and subsequently
involved in the final stage of cellular detoxification. Similar to P-
gp, this ABC transporter has broad substrate specificity, compris-
ing of many conjugated organic anions and drug metabolites. In
addition, MRP2 also plays an essential part in bilirubin glucurono-
side and bile salt sulfate/glucuronoside biliary excretion [9,10].
The role of ABCC2 polymorphisms in DILI is currently unclear
with controversial results between studies [11,12].
Multidrug resistance protein 3 (MDR3) is encoded by the
ABCB4 gene and highly expressed in the liver. This ABC
transporter is not believed to play a major role in drug transport,
but is essential for biliary phosphatidylcholine (PC) secretion. PC
combines with bile salts to form mixed micelles, which prevent
against damage caused by detergent-like bile salts activity. With
insufficient PC concentration, bile salts transported into the bile by
BSEP can potentially solubilize cell membranes resulting in biliary
toxicity [13]. Hence, genetic variations comprising MRD3 activity
could potentially lead to DILI, as demonstrated for BSEP.
Due to the participation of ABC transporters in drug
elimination and their known capacity to produce serious hepatic
conditions [14,15], flawed ABC transporter functions as a
consequence of genetic variations could contribute to an increased
risk of drug-induced hepatotoxicity. In this study we have focused
on ten polymorphisms located in ABCB1, ABCB4 and ABCC2. The
ABCC2 polymorphisms were selected based on previous DILI
association studies in ethnically different cohorts [11,12]. The
functional effects of the polymorphisms in the other two genes are
relatively unknown with regards to DILI. However, previous
studies have shown that the selected ABCB1 polymorphisms may
affect serum drug concentration [16,17]. In addition, the selected
ABCB4 polymorphism changes an evolutionary conserved amino
acid, which could lead to altered protein physiochemical
properties [18]. Hence, our aim in this study was to analyse the
influence of selected genetic variations in ABC transporters on the
risk of DILI development and clinical presentations in a large
Spanish DILI cohort.
Material and Methods
Subjects and study protocol
A total of 141 DILI cases were selected from those submitted to
the Spanish DILI Registry, a collaborative network established in
1994 to prospectively identify cases of DILI in a standardized
manner. The criteria for DILI at the time of subject inclusions in
the study were: an increase in alanine transaminase (ALT) $3
times the upper limit of normal (xULN) or $2 xULN of alkaline
phosphatase (ALP). However, 93% of the cases also fulfilled the
more recent DILI criteria established by Aithal and coworkers:
ALT $5 xULN or ALT $3 xULN + total bilirubin (TBL) $2
xULN or ALP $2 xULN [19]. The pattern of liver injury was
classified based on R value calculations as previously described
[20]. A detailed description of the operational structure of the
registry, data recording and case ascertainment has been reported
elsewhere [21]. As a control group we selected a total of 161
healthy Spanish subjects, unrelated to the DILI patients, without
previous DILI history. These controls were recruited from blood
donors in the Spanish Bone Marrow Donor Registry from the
same geographic region and of similar age and gender distribution.
Ethics statement
The study protocol was approved by the local ethics committee
of the coordinating center at the Hospital Universitario Virgen de
la Victoria (Comité Ético de Investigación) in Málaga, Spain. All
subjects who took part in the study were over 18 years of age. All
subjects gave written informed consent, which conformed to the
current Helsinki Declaration, prior to study enrolment.
DNA extraction and genotyping
Venous blood was obtained from each subject and DNA was
extracted as described previously [22]. Samples and controls were
genotyped for the ABCB1 c.1236T.C (p.Gly412Gly, rs1128503),
c.3435T.C (p.Ile1145Ile, rs1045642), ABCB4 c.1954A.G
(p.Arg652Gly, rs2230028) and ABCC2 c.-1549A.G (rs1885301),
c.-24C.T (rs717620), c.1249G.A (p.Val417Ile, rs2273697),
c.3972C.T (p.Ile1324Ile, rs3740066) and c.4544G.A (p.Cy-
s1515Tyr, rs8187710) using a validated 59-nuclease PCR based
assay with allele specific fluorescent probes (TaqMan SNP
Genotyping Assays, Applied Biosystems, Foster City, CA, USA)
as previously described [23]. In short, 10 ng of sample DNA in
25 mL of reaction solution containing 12.5 mL of the 26Taqman
Universal PCR Mix (Applied Biosystems), and 1.25 mL of pre-
developed assay reagent from the SNP genotyping product
(Applied Biosystem), containing two primers and two MGB-
Taqman probes was used for each sample reaction. Reaction
conditions consisted of pre-incubation at 95uC for 10 min followed
by 40 cycles of 95uC for 15 s and 60uC for 1 min.
Due to the nature of the ABCB1 2677G.T/A (p.Ala893Ser/
Thr, rs2032582) and ABCC2 -1774G.del (rs369192412) poly-
morphisms, these were genotyped by direct sequencing with Big
dye terminator cycle sequencing kit (Applied Biosystems, Foster
City, CA, USA) of a 224 and 554 basepair amplicon, respectively,






Genotype distributions and allelic frequencies were analysed in
DILI patients and controls using the comparison of proportions
test, a derivative of the Fisher’s exact test. Bonferroni’s correction
for multiple tests, whereby the probability value (P) was multiplied
by the number of genotypes or alleles compared to give a
corrected P value (Pc), was performed in order to account for
problems of significant associations arising by chance after
multiple comparisons. Haplotype frequencies were performed for
the ABCC2 and ABCB1 polymorphisms using the Haploview 4.1
software (Broad Institute, Cambridge, MA, USA). Due to software
incompatibility with three allelic polymorphisms the ABCB1
2677G.T,A was considered as 2677G.T. Hence, six cases and
seven controls with an ABCB1 2677A allele were omitted from the
haplotype analysis. Allele combination frequencies formed by
ABC Transporter Gene Polymorphisms and DILI
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ABCC2/ABCB1 and ABCB1/ABCB4 in 97 DILI patients and 125
controls were also predicted using Haploview 4.1.
Means were compared by Student’s t test for independent
sample. Analysis of variance (ANOVA) was used for comparison of
groups. Where variables did not follow a normal distribution, a
nonparametric Kruskal-Wallis analysis was performed. All anal-
yses were performed using the SPSS 19.0 statistical software
package (SPSS Inc, Chicago, IL, USA) and p,0.05 was
considered to be statistically significant. Statistical power calcula-




A total of 141 DILI patients were included in the study of which
73 were males and 68 females. The mean age at DILI onset was
54 years, ranging from 14 to 83 years. The predominant pattern of
injury, based on the R value calculated from the first blood sample
analysis after DILI onset, was hepatocellular (n = 77) followed by
mixed (n = 36) and cholestatic (n = 28). The main causative
therapeutic drug group was antiinfectives (37%), followed by
musculo-skeletal (13%), nervous system (12%), cardiovascular
(11%) and antineoplastic drugs (7%). Of the 141 patients only one
developed fulminant hepatic failure and required a liver
transplantation. Applying the Council for International Organi-
zations of Medical Science (CIOMS) causality scale the 141 cases
were classified as 78 (55%) highly probable, 56 (40%) probable
and 7 (5%) possible DILI cases. Demographics, clinical and
laboratory parameters of the 141 DILI cases included in the study
are outlined in Table 1.
ABCB1, ABCB4 and ABCC2 polymorphisms
In search for genetic differences DILI patients and controls were
genotyped for 10 specific polymorphisms located in ABCB1
(1236T.C, 2677G.T/A and 3435T.C), ABCB4 (1954A.G)
and ABCC2 (-1774G.del, -1549A.G, -24C.T, 1249G.A,
3972C.T and 4544G.A). No significant differences were found
in either genotype distribution or allele frequency between cases
and controls for any of the individual polymorphisms (Table 2).
The statistical power to find significant differences with an odds
ratio of 2 in our cohort was 78%–88%, except for the less
polymorphic ABCB1 2677G.A (24%), ABCB4 1954A.G (65%)
and ABCC2 -1774G.del (65%) and 4544G.A (59%). The
ABCC2 -1774deldel genotype was not present in any of the
controls, which prevented a statistical analysis using the compar-
ison of proportions method. However, when analysing the ABCC2
-1774deldel distribution between cases and controls using the
Fisher’s exact test the difference was found to be statistically
significant (p = 0.014). As the MRP2 transporter, encoded by
ABCC2, is known to transport various conjugated drug metabolites
a smaller subgroup of 22 DILI cases induced by drugs undergoing
glucuronidation was also analysed. None of the alleles corre-
sponding to the six ABCC2 polymorphisms were however found to
correlate with DILI risk in this subgroup (data not shown).
Linkage disequilibrium (LD) and haplotype analysis
Strong pairwise LD was seen between several of the ABCC2
polymorphisms in particular among -1549A.G, -24C.T and
1249G.A, which formed a haplotype block (Figure 1). The major
haplotypes formed by the six ABCC2 polymorphisms were equally
distributed between DILI patients and controls (Table 3). Similar
results were obtained when analysing haplotype frequencies
Table 1. Demographics, clinical and laboratory parameters of
the 141 DILI cases included in the study.
Demographics
Mean age, years (range) 54 (14–83)
Male/female 73/68
Body mass index, mean 6SD 26.764.3
Time to DILI onset
, 30 days 77 (54.6%)
30–90 days 36 (25.5%)
.90 days 28 (19.9%)
Clinical presentation, n (%)
Jaundice 97 (68.8%)
Hospital admission 75 (53.2%)




Biochemical parameters*, mean ±SD (median)
TBL xULN 7.067.7 (4.3)
ALT xULN 18.5621.5 (9.1)
ALP xULN 2.462.0 (1.7)
*First available serum analysis after DILI onset, TBL: total bilirubin, ALT: alanine
transaminase, ALP: alkaline phosphatase, xULN: times the upper limit of normal
doi:10.1371/journal.pone.0094675.t001
Figure 1. Linkage disequilibrium (LD) plot of ABCC2 polymor-
phisms. Each square represents a pairwise LD relationship formed
between the two single polymorphisms with D’ values multiplied by
100 shown inside the squares. The shade of grey indicates the degree of
LD significance. Dark grey squares represent statistically significant LD
as measured by D’ up to a maximum of 1. White squares indicate D’
values less than 1 with no statistically significant LD. The three
polymorphisms -1549G.A, -24C.T and 1249G.A were found to form
a separate haploblock with evidence of strong LD according to the
Gabriel algorithm.
doi:10.1371/journal.pone.0094675.g001
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formed by the three SNPs constituting the haploblock (data not
shown). The three ABCB1 SNPs were found to be in LD, with D’
values of 0.84, 0.81 and 0.62 for the SNP pairs 1236T.C/
2677G.T, 2677G.T/3435T.C and 1236T.C/3435T.C,
respectively (Figure 2). The ABCB4 1954A.G polymorphism
was also included in the LD analysis due to ABCB4 being adjacent
to ABCB1 on chromosome 7. The ABCB4 1954A.G and ABCB1
3435 T.C SNP pair demonstrated a D’ value of 0.89, thought the
R2 value only reached 0.058 (Figure 2).
Similar to the results for the ABCC2 haplotypes, none of the
major ABCB1 haplotypes differed between DILI patient and
controls in terms of frequency (Table 4). Allele combinations
formed by the studied ABCC2 and ABCB1 polymorphisms as well
as ABCB1 and ABCB4 were also analysed in search for
distinguishing genetic features. No allele combinations formed
by the different transporter genes presented any significant
associations with DILI development (Table 5 and Table 6).
ABC transporter gene polymorphisms and clinical
parameters
Phenotypic parameters, such as type of liver injury, serum total
bilirubin (TBL), alanine transaminase (ALT) and alkaline phos-
phatase (ALP) values, at presentation were analysed according to
genotypes in the 10 different polymorphisms. Patients with the
ABCC2 -24TT genotype (n = 10, 1 case without TBL data) were
found to have a higher tendency towards elevated TBL values with
a mean value of 12.2 xULN vs 6.5 (CC, n = 63, 3 cases without
TBL data) and 6.1 (CT, n = 37, 3 cases without TBL data)
(p = 0.06) at presentation. The -24TT carriers also demonstrated
higher maximum TBL, although not reaching statistical signifi-
cance (TT: 12.5 vs CC: 7.2 and CT: 7.1 xULN) (p = 0.23). Seventy
percent of the TT carriers reached a maximum TBL value of
more than 10 xULN, while the corresponding proportion for the
CC and CT carriers were 25% and 21%, respectively (p = 0.011)
(Figure 3). Post hoc analyses with the Fisher’s exact test
demonstrated statistically significant differences between CC and
Table 2. Genotype distribution and allele frequency of 10
polymorphisms situated in the genes ABCC2 (-1771G.delG, -
1549G.A, -24C.T, 1249G.A, 3972C.T, 4544G.A), ABCB1
(1236T.C, 2677G.T/A, 3435T.C) and ABCB4 (1954A.G).
Genotype distribution, n (%) Allele frequency, n (%)
Polymorphism DILI Control DILI Control
ABCC2 n = 117 n = 156 n = 234 n = 312
c.-1774G.del
GG 100 (85) 123 (79) G 212 (91) 279 (89)
Gdel 12 (10) 33 (21) delG 22 (9) 33 (11)
deldel 5 (4) 0 (0)
c.-1549G.A
GG 34 (29) 36 (23) G 115 (49) 144 (46)
GA 47 (40) 72 (46) A 119 (51) 168 (54)
AA 36 (31) 48 (31)
c.-24C.T
CC 66 (56) 86 (55) C 172 (73) 229 (73)
CT 40 (34) 57 (37) T 62 (26) 83 (27)
TT 11(9) 13 (8)
c.1249G.A
GG 73 (62) 106 (68) G 183 (78) 257 (82)
GA 37 (32) 45 (29) A 51 (22) 55 (18)
AA 7 (6) 5 (3)
c.3972C.T
CC 34 (29) 48 (31) C 123 (53) 168 (54)
CT 55 (47) 72 (46) T 111 (47) 144 (46)
TT 28 (24) 36 (23)
c.4544G.A
GG 104 (89) 130 (83) G 220 (94) 284 (91)
GA 12 (10) 24 (15) A 14 (6) 28 (9)
AA 1 (1) 2 (1)
ABCB1 n = 119 n = 152 n = 238 n = 304
c.1236T.C
TT 17 (14) 28 (18) T 88 (37) 119 (39)
CT 54 (45) 63 (41) C 150 (63) 185 (61)
CC 48 (40) 61 (40)
c.2677G.T, A
GG 44 (37) 64 (42) G 146 (61) 190 (62)
GT 50 (42) 58 (38) T 83 (35) 107 (35)
GA 8 (7) 4 (3) A 9 (4) 7 (2)
TT 16 (13) 23 (15)
TA 1 (1) 3 (2)
AA 0 (0) 0 (0)
c.3435T.C
TT 19 (16) 29 (19) T 95 (40) 126 (41)
CT 57 (48) 68 (45) C 143 (60) 178 (59)
CC 43 (36) 55 (36)
ABCB4 n = 134 n = 161 n = 268 n = 322
c.1954A.G
AA 112 (84) 131 (81) A 246 (92) 290 (90)
AG 22 (16) 28 (17) G 22 (8) 32 (10)
GG 0 (0) 2 (1)
doi:10.1371/journal.pone.0094675.t002
Figure 2. Linkage disequilibrium (LD) plot of ABCB1 (1236T.C,
2677G.T, 3435T.C) and ABCB4 (1954A.G) polymorphisms.
Each square represents a pairwise LD relationship formed between the
two single polymorphisms with D’ values multiplied by 100 shown
inside the squares. The shade of grey indicates the degree of LD
significance. Dark grey squares represent statistically significant LD as
measured by D’ up to a maximum of 1. White squares indicate D’ values
less than 1 with no statistically significant LD.
doi:10.1371/journal.pone.0094675.g002
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TT carriers (p = 0.0074) as well as CT and TT carriers (p = 0.0059)
in terms of proportion of cases with bilirubin levels above 10
xULN. In addition to being more prone to higher TBL elevations,
all the ABCC2 -24TT carriers shared the same ABCC2 diplotype,
being homozygous for the -1774G, -1549A, -24T, 1249G, 3972T
and 4544G alleles and 73% developed hepatocellular type of
injury.
Patients homozygous for the 1249A allele (n = 7) were all found
to have developed hepatocellular injury, but only 29% reached a
maximum TBL value of more than 5 xULN. All of these patients
were also homozygous for the -1549G and -24C alleles with the
majority being homozygous for the -1774G, 3972C and 4544G
alleles. No further clinical or biochemical parameters were found
to differ between genotypes and alleles for any of the analysed
ABCB1, ABCB4 and ABCC2 polymorphisms.
Discussion
Based on their crucial role in drug metabolism and maintenance
of liver homeostasis ABC transporters could play a role in DILI
development. A defect in any of these transporters can affect
biliary clearance and subsequently delay the elimination of toxic
substances, including drug metabolites. This has been confirmed
through diseases such as intrahepatic cholestasis and Dubin-
Johnson syndrome caused by mutations in ABCB4 and ABCC2,
respectively. In this study we analysed a total of 10 polymorphisms
located in ABCB1, ABCB4 and ABCC2 in DILI patients and
healthy controls and found that none of the individual polymor-
phisms were associated with DILI development. The statistical
power to detect differences with an odds ratio of 2 was relatively
high (.75%) for most of the polymorphisms. However, in the
polymorphisms with lower minor allele frequencies and conse-
quently lower statistical power, in particular ABCB1 2677G.A
and ABCC2 4544G.A, it is possible that this may have
contributed to the inability to detect significant differences
between the cases and controls. Hence, to ascertain that these
polymorphisms have no role in DILI development, despite our
findings, requires larger cohorts. Furthermore, our controls were
not drug-matched and although healthy at the time of the blood
extraction (and having no recorded DILI episode) the possibility
that some of them could develop DILI at a later stage cannot be
absolutely discarded. Due to the low incidence rate of idiosyncratic
DILI (1/10 000–1/100 000 user of a specific treatment) however,
we hold it for very unlikely that a large proportion of the controls
would be susceptible to developing DILI. In addition, the main
causative agents in our DILI cases were antiinfectives and
musculo-skeletal drugs, which are widely used in the Spanish
community. Hence, it is likely that many of the controls in fact
have been exposed to the causative agents corresponding to the
DILI cases. In an earlier study we compared genotype data of an
additional ABC transporter polymorphism in this control cohort
with those of controls with recorded drug intakes and found no
significant differences between the two cohorts [3].
We found, however, that there was a tendency towards a DILI
association for homozygous ABCC2 -1774del carriers as this
genotype was not present in any of the controls. Evidently, this
needs to be confirmed in a larger cohort, which could be a difficult
task due to the rarity of this genotype in conjunction with DILI
itself being a relatively rare condition. Nevertheless, the -
1774deldel genotype has been found to play a role in cholestat-
ic/mixed type of DILI development in a Korean population,
where this genotype is more common than seen in Caucasians
[11]. The same study also demonstrated that the -1774del allele
reduced the level of gene expression compared to the G allele.
Furthermore, the -1774G.del polymorphism has been shown to
be in strong linkage disequilibrium with rs3740065, a polymor-
phism located in intron 29 of the same gene, in a Japanese
population [24]. Interestingly, the rs3740065 polymorphism
provided the highest association among genes involved in drug
metabolism in a recent genome-wide association study on 783
DILI patients [25]. Although, the extent of linkage disequilibrium
between -1774G.del and rs3740065 in Caucasians is currently
unknown.
Table 3. Predicted haplotype frequencies of transporter gene polymorphisms.
-1774G.del -1549A.G -24C.T 1249G.A 3972C.T 4544G.A DILI (2n = 234)
Controls
(2n = 312) p
G A T G T G 58 (25%) 78 (25%) 0.944
G G C A C G 42 (18%) 48 (15%) 0.444
G G C G C G 36 (15%) 46 (15%) 0.805
G A C G T G 34 (14%) 44 (14%) 0.927
del G C G C G 18 (7.7%) 29 (9.3%) 0.548
G A C G C A 13 (5.6%) 21 (6.7%) 0.571
Major haplotypes formed by ABCC2 polymorphisms -1774G.del, -1549A.G, -24C.T, 1249G.A, 3972C.T and 4544G.A in DILI patients and controls.
The table outlines major haplotypes with a predicted frequency higher than 5% in the control population. The minor alleles in the study cohort are marked in
underlined bold faced letters.
doi:10.1371/journal.pone.0094675.t003






(2n = 290) p
C G C 114 (52%) 138 (48%) 0.343
T T T 69 (31%) 82 (28%) 0.475
T G C 15 (6.8%) 24 (8.3%) 0.563
C G T 7 (3.2%) 18 (6.2%) 0.123
Major haplotypes formed by ABCB1 polymorphisms 1236C.T, 2677G.T and
3435T.C in DILI patients and controls.
The table outlines major haplotypes with a predicted frequency higher than 5%
in the control population.
The minor alleles in the study cohort are marked in underlined bold faced
letters.
doi:10.1371/journal.pone.0094675.t004
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Koreans homozygous for the ABCC2 -1549A and 3972T alleles
appear to be more prone to developing hepatocellular type of
DILI [11], though no associations were seen with these genotypes
in the Spanish cohort. Substantial differences in allele frequencies
between the Korean and our control cohort may have contributed
to the discrepant results. In particular, 3972C.T has been shown
to vary considerably between Asians and Caucasians with regards
to allele and associated haplotype frequencies [24]. It is also
possible that DILI risk alleles differ depending on the causal agent.
The Korean cohort, in which various ABCC2 risk alleles were
identified, contained mostly herbal remedy-induced hepatotoxicity
cases, while our cohort included a larger variety of causal agents,
mainly conventional pharmaceuticals. The presence of drug-
specific risk alleles is supported by a recent analysis of seven
ABCC2 polymorphisms in a different Korean cohort consisting of
antituberculosis treatment-induced hepatotoxicity cases. This
study could not reproduce the results found in the earlier Korean
cohort, as no associations were found for any of the individual
polymorphisms or haplotypes [26]. Our results also differ from
those of Daly and coworkers, who found a significant variation in
the ABCC2 -24C.T genotype distribution between British DILI
patients and controls [12]. The fact that the British study was
restricted to diclofenac-induced DILI and only 3 of our 117 cases
analysed were due to diclofenac may have attributed to the
different findings.
No ABCC2 haplotypes were found to be over- or underrepre-
sented in the DILI cohort. However, a smaller group of patients
with substantial TBL elevations were identified based on sharing
an identical diplotype (-1774GG/-1549AA/-24TT/1249GG/
3972TT/4581GG). The ABCC2 -24T/1249G/3972T haplotype
has been shown to yield lower protein expression and efflux rate in
vitro compared to the more common -24C/1249G/3972C
haplotype, presumably due to variations in mRNA secondary
structures and resultant posttranscriptional modifications [27].
One might speculate that the extended ABCC2 haplotype -
1774G/-1549A/-24T/1249G/3972T/4544G has a similar func-
tional effect, based on indications of reduced expression for the -
1549A and 4544G allele [11,28]. This haplotype, however, does
not appear to enhance the risk of DILI development as it was seen
to be the most common haplotype present in both cases and
controls. Neither was the homozygous diplotype more prevalent in
the DILI cases. Nevertheless, the higher TBL values seen with this
diplotype could be an effect of reduced ABCC2 activity, due to
having two copies of a haplotype assumed to decrease the
transporter function, in addition to the cellular strain of DILI. The
formation of reactive metabolites from the parent drug is
combated through detoxification processes, which often involve





(2n = 250) P
-
1774G.del -1549A.G -24C.T 1249G.A 3972C.T 4544G.A 1236C.T 2677G.T 3435C.T
G A T G T G C G C 27 (14%) 26 (10%) 0.213
G A T G T G T T T 15 (7.7%) 23 (9.2%) 0.647
G A C G T G C G C 16 (8.2%) 20 (8.0%) 0.9.25
G G C A C G C G C 15 (7.7%) 19 (7.6%) 0.9.30
G G C G C G C G C 15 (7.7%) 17 (6.8%) 0.716
G A C G T G T T T 12 (6.2%) 16 (6.4%) 0.949
G G C A C G T T T 13 (6.7%) 13 (5.2%) 0.513
del G C G C G C G C 9 (4.6%) 13 (5.2%) 0.799
Major allele combination formed by ABCC2 (-1774G.del, -1549A.G, -24C.T, 1249G.A, 3972C.T and 4544G.A) and ABCB1 (1236C.T, 2677G.T and 3435T.C)
polymorphisms in DILI patients and controls.
The table outlines major allele combinations with a predicted frequency higher than 5% in the control population. The minor allele in the study cohort is marked in
underlined bold faced letters.
doi:10.1371/journal.pone.0094675.t005
Table 6. Predicted allele combination frequencies of transporter gene polymorphisms.
ABCB1 ABCB4 DILI (2n = 194) Controls (2n = 250) P
1236C.T 2677G.T 3435C.T 1954A.G
C G C A 88 (45%) 96 (38%) 0.141
T T T A 60 (31%) 78 (31%) 0.991
C G C G 12 (6.2%) 20 (8.0%) 0.456
T G C A 13 (6.7%) 17 (6.8%) 0.963
C G T A 6 (3.1%) 14 (5.6%) 0.197
Major allele combination formed by ABCB1 (1236C.T, 2677G.T and 3435T.C) and ABCB4 1954A.G polymorphisms in DILI patients and controls.
The table outlines major allele combinations with a predicted frequency higher than 5% in the control population. The minor allele in the study cohort is marked in
underlined bold faced letters.
doi:10.1371/journal.pone.0094675.t006
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glutathione conjugation [29]. Such glutathione conjugates could
then compete with conjugated bilirubin for MRP2 biliary
excretion, leading to bilirubin being released back into the blood
stream by basolateral transporters, such as MRP3 encoded by the
gene ABCC3, and consequently elevating serum concentrations of
bilirubin glucuronosides. Conjugated bilirubin transport by MRP3
has been demonstrated and hepatic MPR3 induction has been
found in situations of decreased MRP2 activity [30,31].
Allele distributions of the ABCB1 polymorphisms focused on in
this study are known to vary considerably between different ethnic
populations. However, our results were comparable to those
established earlier in Caucasian populations [32]. The functional
effects of these polymorphisms and their roles in drug transport are
still controversial [33]. Nevertheless, the 3435T allele is thought to
cause translational problems due to the formation of a rare codon,
affecting the timing of cotranslational folding and membrane
insertion and consequently could affect substrate binding and
specificity, despite being a synonymous polymorphism [17]. Few
studies have demonstrated convincing associations between
ABCB1 polymorphisms and DILI development, though the ABCB1
3435T allele has been associated with reduced risk of nevirapine
hepatotoxicity in several independent studies [6-8]. We, however,
did not find this allele to have any major impact on the risk of
DILI in the current study, possibly due to the lack of nevirapine
cases in our ethnically different cohort.
In accordance with previous results the three ABCB1 polymor-
phisms studied were found to be in linkage disequilibrium with low
haplotype diversity. The two major haplotypes 1236C/2677G/
3435C and 1236T/2677T/3435T were predicted to be present in
approximately 80% of the cohort. The difference between ABCB1
haplotypes in terms of transporter activity is unclear. Our study,
however, does not support evidence for ABCB1 haplotypes having
differential effects on DILI development. Interestingly the ABCB4
1954A.G and ABCB1 3435T.C SNP pair were seen to have a
high D’ value, suggesting possible LD, though this is not supported
by the low R2 value. Due to the low frequency of the ABCB4 G
allele and the large distance between the SNPs (.80 kbp) this
finding should be considered with caution. Nevertheless, long
distance LD has been reported in ABCB1 stretching across to the
nearby ABCB4 gene [34].
Both MRP2 and P-gp have wide substrate specificity with
certain degree of overlap, in addition to their co-localization on
the hepatocyte canalicular membrane. We therefore hypothesised
that reduced activity in one of these transporters may be
compensated for by the other. Hence, specific allele combinations
formed by these two genes could potentially shed light onto the
underlying mechanism of DILI development. It is possible that
putative ABCB1/ABCC2 allele combinations effecting DILI
development may require DILI cases with the same causative
agent or those forming similar metabolites in terms of structural
elements. Hence, the pooling of DILI cases induced by a wide
range of causal agents could have diluted potentially different
allele combination frequencies.
In conclusion, due to the complexity of the human efflux
transporter system it is difficult to determine its potential role in
DILI development. Our data do not support a role for the selected
polymorphisms in ABC transporter genes ABCB1, ABCB4 and
ABCC2 in DILI development in Spanish patients, neither
individually nor in combinations. The -1774del allele in ABCC2
was however restricted to DILI cases and could potentially
contribute to enhanced DILI susceptibility. In addition, this study
highlights the differential effect of specific ABC transporter alleles
in ethnically different cohorts.
Acknowledgments
We wish to thank the Spanish DILI Registry collaborators for their help
with case recruitment.
Participating clinical centres:
Hospital Universitario Virgen de la Victoria, Málaga (coordinating
centre): R.J. Andrade, M.I. Lucena, C. Stephens, M. Garcı́a-Cortés, A.
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Hospital de Mendaro, Guipúzcoa: A. Castiella, E.M. Zapata.
Hospital Alto Deba Mondragón, Guipúzcoa: P. Otazua
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Figure 3. Serum total bilirubin elevations in 110 Spanish DILI
patients classified by ABCC2 -24C.T genotypes. Bilirubin
measurements from the first available blood test after DILI initiation
was used for this analysis. Footnote: *p = 0.0074 (CC vs TT), **p = 0.0059
(CT vs TT), TBL: total bilirubin, xULN: times the upper limit of normal.
doi:10.1371/journal.pone.0094675.g003
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